The present disclosure is directed to a cleavable agent for enhanced magnetic resonance generally corresponding to the formula Y-L-R, wherein Y represents a catalyst-binding moiety having at least one isotopically labeled heteroatom, L represents a cleavable bond, and R represents a hyperpolarized payload having at least one isotopically labeled carbon. Also disclosed herein is a method of cleaving the cleavable agent for enhanced magnetic resonance.

Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V and formula VI and the methods for the treatment of eye disorders and skin diseases and may be formulated for the topical eye drop, topical paste, ocular solution, device-drug delivery, oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, cream, dermal ointment, gels, lotions, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of skin diseases such as acne, rosacea and eye disorders such as ocular redness, glaucoma, presbyopia, IOP, cataract, dry eye and oGVHD.

The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V and formula VI and the methods for the treatment of eye disorders and skin diseases and may be formulated for the topical eye drop, topical paste, ocular solution, device-drug delivery, oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, cream, dermal ointment, gels, lotions, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of skin diseases such as acne, rosacea and eye disorders such as ocular redness, glaucoma, presbyopia, IOP, cataract, dry eye and oGVHD.

Provided are a curing accelerator for an oxidative polymerization type unsaturated resin having a high curing accelerating ability, and a printing ink and a coating material. Specifically, there are provided a curing accelerator for an oxidative polymerization type unsaturated resin, containing a metal complex () having an anion compound () represented by the following structural formula (1-1) or (1-2) as a ligand: ##STR00001##
wherein R.sup.1 is any one of a hydroxyl group, an amino group, a nitro group, a nitroso group, a sulfo group, a halogen atom, a hydrocarbon group which may have a substituent, a hydrocarbon oxy group which may have a substituent, and a hydrocarbon oxycarbonyl group which may have a substituent, m is 0 or an integer of 1 to 3, n is 0 or an integer of 1 to 6, and X is any one of a carboxylate group, a hydrogen atom, and the R.sup.1 group.

Provided are a curing accelerator for an oxidative polymerization type unsaturated resin having a high curing accelerating ability, and a printing ink and a coating material. Specifically, there are provided a curing accelerator for an oxidative polymerization type unsaturated resin, containing a metal complex () having an anion compound () represented by the following structural formula (1-1) or (1-2) as a ligand: ##STR00001##
wherein R.sup.1 is any one of a hydroxyl group, an amino group, a nitro group, a nitroso group, a sulfo group, a halogen atom, a hydrocarbon group which may have a substituent, a hydrocarbon oxy group which may have a substituent, and a hydrocarbon oxycarbonyl group which may have a substituent, m is 0 or an integer of 1 to 3, n is 0 or an integer of 1 to 6, and X is any one of a carboxylate group, a hydrogen atom, and the R.sup.1 group.

Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

The invention provides a compound having a GLUT9 inhibitory activity. The compound is of Formula [I] ##STR00001##
wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof.

The invention provides a compound having a GLUT9 inhibitory activity. The compound is of Formula [I] ##STR00001##
wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof.

The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R.sup.1 is a saturated or unsaturated, optionally substituted C.sub.1-C.sub.15 hydrocarbyl group, wherein the atom of R.sup.1 which is attached to the sulfur atom of the sulfonylurea group is not a ring atom of a cyclic group; and R.sup.2 is a cyclic group substituted at the -position, wherein R may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP.sub.3.

##STR00001##